样式: 排序: IF: - GO 导出 标记为已读
-
Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-19 Simon Woelfel, Stephan Brand
We thank Drs. Alexander and Caldera for their stimulating and compelling editorial that excellently contextualised our study evaluating the immunogenicity of original and variant-adapted COVID-19 mRNA vaccines in patients with inflammatory bowel disease (IBD) and healthy controls [1, 2]. To date, the STAR SIGN study has evaluated immunity against wild-type SARS-CoV-2 and the omicron BA.1, BA5, BQ.1
-
Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-19 Konstantinos Papamichael, Adam S. Cheifetz
Numerous exposure–outcome relationship studies demonstrate a positive correlation between therapeutic biologic drug concentrations and favourable outcomes in immune-medicated inflammatory disorders including inflammatory bowel disease (IBD) [1, 2]. In the same vein, low drug concentrations are associated with loss of response and immunogenicity [1, 3]. Furthermore, post hoc analyses of randomised controlled
-
Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-18 Sung Noh Hong, Joo Hye Song, Sung Jin Kim, Yoon Ha Park, Chang Wan Choi, Ji Eun Kim, Eun Ran Kim, Dong Kyung Chang, Young‐Ho Kim
-
Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-18 Giovanni Cammarota, Lucrezia Laterza, Stefano Bibbò, William Fusco, Tommaso Rozera, Eugenio Di Brino, Serena Porcari, Franco Scaldaferri, Gianluca Ianiro, Antonio Gasbarrini, Alessandro Armuzzi
-
Management of Muscle Cramps in Patients With Cirrhosis: A Systematic Review of Randomised Controlled Trials Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-16 Andrew T. Roberts, Joseph Makar, Jonathan Abdelmalak, Marie Sinclair, Adam Testro, Avik Majumdar
-
Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-15 Mohsin F. Butt, Maura Corsetti
The Rome criteria, first published in 1994 and currently in their fourth iteration, are widely considered to be the gold standard symptom-based criteria to diagnose disorders of gut-brain interaction (DGBI), formerly known as functional gastrointestinal diseases [1]. To inform the upcoming Rome V criteria, due for publication in 2026, the Rome Foundation analysed the effects of modifying symptoms (e
-
Meta‐Analysis: Evaluating Placebo Rates Across Outcomes in Eosinophilic Oesophagitis Randomised Controlled Trials Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-15 Angelica Rivas, Newaz Shubidito Ahmed, Yuhong Yuan, Anila Qasim, David B. O'Gorman, Brian G. Feagan, Vipul Jairath, Albert J. Bredenoord, Evan S. Dellon, Christopher Ma
-
Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-14 Francesco Paolo Russo, Alberto Ferrarese
Acute-on-chronic liver failure (ACLF) is a severe condition characterised by high short-term mortality, requiring rapid diagnosis, prompt treatment of trigger factors and appropriate prognostic evaluation to guide patients towards the best therapeutic options. Although several scores, such as the model for end-stage liver disease (MELD) and the CLIF-C ACLF score, have been proposed over time to assess
-
Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-14 Jiong Yu, Xinyi Chen, Guoqiang Cao, Qiaoling Pan, Chenjie Huang, Rui Luo, Xiaoqing Lu, Xiaoxiao Chen, Tan Li, Haijun Huang, Jian Wu, Lanjuan Li, Hongcui Cao
We extend our sincere gratitude to Dr. Francesco Paolo Russo and Alberto Ferrarese for their thorough evaluation and professional insights on our study [1]. We are gratified by their recognition of the potential of the age-adjusted Charlson Comorbidity Index for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure (aCCI-HBV-ACLF) score in enhancing the accuracy of short-term and medium-term prognostic
-
Letter: Insulin‐Like Growth Factor‐1 in Cirrhosis Is Linked to Hepatic Dysfunction and Fibrogenesis and Predicts Liver‐Related Mortality Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-14 Okasha Tahir, Muhammad Muzamil Rafique, Abdul Ghani Khan, Asia Rajab, Umama Alam, Muhammad Umar, Laiba Shamim, Ayesha Hidayat
We read the article published in your esteemed journal titled, “Insulin-like growth factor-1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver-related mortality” by Hartl et al. with great interest. We appreciate the authors for investigating the prognostic role of insulin-like growth factor-1 (IGF-1) in advanced chronic liver disease (ACLD) patients [1]. While the study
-
Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-13 Virginia Solitano, Guangyong Zou, Vipul Jairath
We thank Dr. Schildkraut et al. for their thoughtful commentary and the acknowledgment of the importance of our study in demonstrating that existing bowel preparation quality assessment instruments, typically used in the general population, are also reliable and valid for patients with Crohn's disease (CD) [1]. The implications of these findings are that instrument selection for use in clinical practice
-
Letter: Bowel Preparation Quality in Patients With Crohn's Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-13 Tamar Schildkraut, Nik (John) S. Ding, John David Chetwood
Adequate bowel preparation is crucial for optimal visualisation and lesion detection and remains a key determinant of colonoscopy quality [1, 2]. Up to one-quarter of colonoscopies are conducted with inadequate bowel preparation, leading to reduced diagnostic yield and detection of nonpolypoid flat lesions, prolonged procedure time and an increased burden of repeat colonoscopies [2, 3]. Several validated
-
Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-10 Mitchell Shiffman, K. Rajender Reddy, Michael D. Leise, Kamran Qureshi, Alastair D. Smith, Steve Helmke, John Kittelson, Michael P. McRae, Joanne C. Imperial, Gregory T. Everson
-
Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-12 Riccardo Vasapolli, Florent Ailloud, Beate Spießberger, Peter Malfertheiner, Sebastian Suerbaum, Christian Schulz
-
Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Diseases Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-11 Isabel Carbery, Oliver Todd, Matthew Hale, Christopher J. Black, Andrew Clegg, Christian P. Selinger
-
Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-11 Jian Wang, Zhiyi Zhang, Shengxia Yin, Shaoqiu Zhang, Li Zhu, Yifan Pan, Tao Fan, Fei Cao, Ye Xiong, Chao Jiang, Guiyang Wang, Yue Yang, Bei Jia, Jiacheng Liu, Juan Xia, Xiaomin Yan, Jie Li, Chuanwu Zhu, Xingxiang Liu, Yuxin Chen, Chao Wu, Rui Huang
-
Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-11 Derek D. Satre, Dhweeja Dasarathy, Steven L. Batki, Michael J. Ostacher, Hannah R. Snyder, William Hua, Priti Parekh, Amy M. Shui, Ramsey Cheung, Alexander Monto, Robert J. Wong, Jennifer Y. Chen, Meimei Liao, Michele Tana, Po‐Hung Chen, Christina G. Haight, Taylor Fakadej, Mandana Khalili
-
Portal Hypertensive Gastropathy and MELD-Na Score Predict Recurrent Gastrointestinal Bleeding After TIPSS: An ALTA Group Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-05 Kelly Hu, Mai Sedki, Allison Kwong, Andrew Kesselman, Kanti Pallav Kolli, Giuseppe Morelli, Erin Spengler, Adnan Said, Jennifer Lai, Archita Desai, Sonali Paul, Catherine Frenette, Michael Fallon, Margarita German, Elizabeth Verna, Justin Boike, Dyanna Gregory, Bartley Thornburg, Lisa VanWagner, Aparna Goel
-
Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-07 Cecilia Katzenstein, Laurie Keefer
In the study by O'Connor et al. participants with primarily IBS-D undergoing a group-based education program on the British Dietary Association's advice for IBS were less likely to achieve the 12-week primary endpoint (50-point reduction in the IBS Symptom Severity Scale) if they had elevated levels of depression or anxiety at baseline [1]. We appreciate the complex undertaking of evaluating psychological
-
Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-07 Anthony O'Connor, Sarah Gill, Elaine Neary, Sarah White, Alexander C. Ford
We thank Drs Katzenstein and Keefer for their editorial on our paper [1, 2]. We fully agree on the need for progress towards an integrated, personalised model of care for patients with disorders of gut-brain interaction. We are aware of the limitations of the Hospital Anxiety and Depression Scale (HADS) and concur that it does not capture all the psychological nuances seen in patients with irritable
-
Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-06 Kuo‐Cheng Wu, I‐Cheng Lee
Click on the article title to read more.
-
Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis—No Surprises but the Usual Suspects Need Greater Attention. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-06 Tom van Gils, Hans Törnblom, Jóhann P. Hreinsson, Börje Jonefjäll, Hans Strid, Magnus Simrén
We thank Dr. Gao and Professor Segal for their interest in our paper on abdominal pain and associated factors in patients with ulcerative colitis (UC) [1, 2]. We agree with them regarding the importance of being aware of abdominal pain in patients with UC, including factors associated with gut-brain interaction, in particular anxiety and depression. Additionally, we agree with the suggestion that predictive
-
Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis—No Surprises But the Usual Suspects Need Greater Attention Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-06 Weilun Gao, Jonathan P. Segal
Pain control is often multidisciplinary and resource-intensive. Pain may be a poorly controlled symptom of ulcerative colitis (UC) culminating in significant patient dissatisfaction. The multicohort study exploring factors associated with abdominal pain in active and quiescent UC highlights the importance of attempting to prevent pain in UC. This may be achieved through understanding the risk factors
-
Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’ Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-06 You‐Jian Xu, Hui‐Ming Pang
Click on the article title to read more.
-
A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-05 Maral Amangurbanova, Daniel Q. Huang, Nabil Noureddin, Kaleb Tesfai, Richelle Bettencourt, Harris Siddiqi, Scarlett J. Lopez, Vanessa Cervantes, Egbert Madamba, Rohit Loomba
-
Editorial: Stopping NUCs—When to Restart NUCs for the Best Outcome? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-05 Melanie Urbanek‐Quaing, Markus Cornberg
The standard treatment of chronic hepatitis B virus (HBV) infection, nucleos(t)ide analogues (NUC), is usually long-term, as HBsAg loss is rarely achieved, which signifies functional cure. Recent evidence suggests that selected HBeAg-negative individuals with prolonged viral suppression and no advanced liver fibrosis can discontinue NUC therapy before HBsAg loss [1]. Studies, including a prospective
-
Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-05 Louise J. M. Alferink, Robert J. de Knegt
Non-selective beta-blockers (NSBBs) are highly effective in preventing variceal bleeding. They are therefore widely used in patients with liver cirrhosis and portal hypertension [1]. Since the landmark study by Lebrec et al. many studies have investigated NSBB use in cirrhosis, including the controversial paper by Serste et al. which suggested increased mortality in decompensated cirrhosis due to NSBB
-
Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-05 Ting Wang, Deli Zou, Xingshun Qi
At present, non-selective beta-blockers (NSBBs) are recommended for the management of clinically significant portal hypertension and primary or secondary prophylaxis of variceal bleeding in cirrhosis [1, 2]. However, as mentioned in the editorial by Alferink and de Knegt [3], the right time to discontinue NSBBs remains inconclusive. The window hypothesis, which has been for the first time proposed
-
Meta‐Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-05 Sahand Karimzadhagh, Elahe Abbaspour, Maryam Shahriarinamin, Pourya Shamsi, Selvana Poursadrolah, Mehrdad Khorasani, Mahzad Daghighi, Arash Malek, Jouan Taheri Talesh, Govind K. Makharia, Mohammad Rostami‐Nejad
-
Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Yu Liu, Liang‐Hao Hu
Click on the article title to read more.
-
Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Mo‐Yao Tan, Ping Zhang, Ming Gao
Click on the article title to read more.
-
Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Katherine L. Stone, Adam S. Faye
As the global prevalence of inflammatory bowel disease (IBD) is increasing, emphasis has been placed on identifying modifiable risk factors that can aid in prevention [1]. Early-life factors, including antibiotic use and the occurrence of infections, increase the risk of developing IBD [2, 3]. This has been demonstrated in several studies, including a large-scale population-based study in Denmark,
-
Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Nina Kimer, Lise Lotte Gluud
Cirrhosis is a debilitating disease with substantial impact on health and prognosis. As the early stages of cirrhosis are asymptomatic or associated with non-specific symptoms, it was previously often diagnosed late in the disease course, after the development complications [1]. New biomarkers, liver scores and elastography have advanced noninvasive diagnosis, and the incidence and prevalence of cirrhosis
-
Editorial: Timely Follow‐Up in Cirrhosis—How Does It Work? Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Max S. Schechter, Hannes Hagström
Click on the article title to read more.
-
Letter: Analysis of ‘Faecal Biomarkers for Diagnosis and Prediction of Disease Course in Treatment‐Naive Patients With IBD’ Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Yuxiang Chen, Wenjian Hu, Fengfeng Qin
Click on the article title to read more.
-
Letter: Analysis of “Faecal Biomarkers for Diagnosis and Prediction of Disease Course in Treatment‐Naïve Patients With IBD”—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Maria Ling Lundström, Maria Lampinen, Marie Carlson, Jonas Halfvarson
Click on the article title to read more.
-
Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Wei‐Zhen Tang, Bo‐Yuan Deng, Tai‐Hang Liu
Click on the article title to read more.
-
Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Muhammad Osama, Safiyyah Ubaid, Maryam Ubaid
Click on the article title to read more.
-
Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease—Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-11-04 Lukas Hartl, Michael Schwarz, Benedikt Simbrunner, Mathias Jachs, Peter Wolf, David Josef Maria Bauer, Bernhard Scheiner, Lorenz Balcar, Georg Semmler, Benedikt Silvester Hofer, Nina Dominik, Rodrig Marculescu, Michael Trauner, Mattias Mandorfer, Thomas Reiberger
Click on the article title to read more.
-
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-29 Simon Woelfel, Joel Dütschler, Daniel Junker, Marius König, Nicole Graf, Claudia Krieger, Samuel Truniger, Vasileios Oikonomou, Georg Leinenkugel, Seraina Koller, Katline Metzger-Peter, Jacqueline Wyss, Niklas Krupka, Nicola Frei, , Werner C. Albrich, Matthias Friedrich, Jan Hendrik Niess, Nicole Schneiderhan-Marra, Alex Dulovic, Benjamin Misselwitz, Wolfgang Korte, Justus J. Bürgi, Stephan Brand
-
Prevalence of Low FIB-4 in MASLD-Related Hepatocellular Carcinoma: A Multicentre Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-27 Darren Jun Hao Tan, Nobuharu Tamaki, Beom Kyung Kim, Karn Wijarnpreecha, Majd Bassam Aboona, Claire Faulkner, Charlotte Kench, Shirin Salimi, Abdul-Hamid Sabih, Wen Hui Lim, Pojsakorn Danpanichkul, Benjamin Tay, Yiqing Teh, John Mok, Benjamin Nah, Cheng Han Ng, Mark Muthiah, Anand V. Kulkarni, Sung Won Lee, Ken Liu, Rohit Loomba, Daniel Q. Huang
-
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-29 Amy Sangam, Banwari Agarwal, Rohit Saha
Patients ‘lumped’ into the syndrome acute-on-chronic liver failure (ACLF) differ on several observable levels: underlying aetiology of cirrhosis, precipitants, number and severity of organ failures (OFs). Despite phenotypic heterogeneity, consensus definitions of ACLF have changed how the condition is understood, recognised and studied. A key unmet need is identifying which elements of ACLF heterogeneity
-
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐on‐Chronic Liver Failure. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-29 Pratibha Garg, Nipun Verma, Ajay Duseja
We sincerely appreciate the insightful Editorial by Sangam et al. regarding our study [1, 2]. We echo the call for harmonising definitions and prognostication in acute-on-chronic liver failure (ACLF) [3]. While the debate over definitions continues, the core concept of ACLF—a rapid deterioration due to an acute insult on chronic liver disease, with organ dysfunction and high short-term mortality—remains
-
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-29 Péter Bacsur, Daniel Shaham, Zuzana Serclova, Tamás Resál, Bernadett Farkas, Patrícia Sarlós, Pál Miheller, Nitsan Maharshak, Meir Zemel, Ariella Shitrit, Anita Bálint, Anna Fábián, Renáta Bor, Zsófia Bősze, Emese Ivány, Zoltán Szepes, Klaudia Farkas, Illés Tóth, György Lázár, Katerina Vlkova, Aneta Tremerova, Petra Zuskova, Szabolcs Ábrahám, Tamás Molnár
-
Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-28 Vivek C. Goodoory, Christy Riggott, Mais Khasawneh, Christopher J. Black, Alexander C. Ford
-
Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-28 Nobuharu Tamaki, Takefumi Kimura, Shun‐Ichi Wakabayashi, Takeji Umemura, Namiki Izumi, Rohit Loomba, Masayuki Kurosaki
Click on the article title to read more.
-
Letter: Filling the Gaps—Enhancing MASLD Prognosis With Imaging, Diverse Populations and Extended Follow‐Up Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-28 Qi‐En Shen, Chengfu Xu
Click on the article title to read more.
-
Editorial: Understanding the Trade‐Offs When Considering Positivity Threshold of Faecal Immunochemical Tests Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-28 Thomas F. Imperiale
The faecal immunochemical test (FIT) is the most used colorectal cancer (CRC) screening test worldwide [1]. FIT is a family of tests, the performance of which varies by brand, positivity threshold and testing interval [2, 3]. Despite myriad studies, the optimal FIT threshold and interval remain elusive. Countries and large health care systems that screen primarily with FIT must decide on the threshold
-
aCCI‐HBV‐ACLF: A Novel Predictive Model for Hepatitis B Virus‐Related Acute‐On‐Chronic Liver Failure Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-26 Xinyi Chen, Feiqiong Gao, Qiaoling Pan, Chenjie Huang, Rui Luo, Xiaoqing Lu, Xiaoxiao Chen, Tan Li, Haijun Huang, Jian Wu, Jiong Yu, Lanjuan Li, Hongcui Cao
-
Early‐Life Infections, Antibiotics and Later Risk of Childhood and Early Adult‐Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-25 Karl Mårild, Tereza Lerchova, Malin Östensson, Henrik Imberg, Ketil Størdal, Johnny Ludvigsson
-
Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-25 Junbin Yan, Yunmeng Nie, Shuo Zhang
LINKED CONTENTThis article is linked to Allende et al paper. To view this article, visit https://doi.org/10.1111/apt.18236
-
Correction to ‘A Personalised Algorithm Predicting the Risk of Intravenous Corticosteroid Failure in Acute Ulcerative Colitis’ Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-25
Croft A, Okano S, Hartel G, Lord A, Walker G, Tambakis G, et al. A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis. Aliment Pharmacol Ther. 2024; 60: 921–933. https://doi.org/10.1111/apt.18190. The units of measurement used to describe C-reactive protein (CRP) concentration in this manuscript were incorrectly reported as mg/mL. This should
-
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-24 Eunice Yewon Lee, Linda Henry, Mindie H. Nguyen
Click on the article title to read more.
-
Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-24 Tom van Gils, Hans Törnblom, Jóhann P. Hreinsson, Börje Jonefjäll, Hans Strid, Magnus Simrén
-
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-24 Qiong Yi, GuangYao Wang, ZongXiang Yue
Click on the article title to read more.
-
Issue Information Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-23
Click on the article title to read more.
-
Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease—Author's Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-23 Eunice Yewon Lee, Linda Henry, Mindie H. Nguyen
LINKED CONTENTThis article is linked to Lee et al papers. To view these articles, visit https://doi.org/10.1111/apt.18242 and https://doi.org/10.1111/apt.18304.
-
Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-23 Wah Loong Chan, Kee Huat Chuah
Chronic liver diseases (CLDs) are a global health concern of significant magnitude, yet their true impact is often underestimated [1]. These diseases contribute to approximately two million deaths each year, accounting for around 4% of all global fatalities [2]. Despite their prevalence, CLDs frequently receive less attention compared to other major health issues. A timely study by Lee et al. which
-
Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-18 Merle Claßen, Benjamin Schiller, Jan Däbritz
Click on the article title to read more.
-
Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-10-18 Aga Luo
Click on the article title to read more.